×
Enjoying ad-free content?
Since July 1, 2024, we have disabled all ads to improve your reading experience.
This commitment costs us $10,000 a month. Your support can help us fill the gap.
Support us
Our journalism is banned in Russia. We need your help to keep providing you with the truth.
Contribute today

Indian Drugmaker to Produce 200M Doses of Russia's Sputnik V

By AFP
Stelis Biopharma is expected to be able to start supplying the Russian vaccine from the second half of the year.  Olga Maltseva / AFP

The developer of Russia's Sputnik V coronavirus vaccine said Friday it had signed a partnership with an India-based drugmaker for the production of 200 million doses of the two-dose jab. 

The Russian Direct Investment Fund (RDIF), which backed the development of Sputnik V, said in a statement it had partnered with Stelis Biopharma "to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine."

Stelis Biopharma is expected to be able to start supplying the vaccine from the second half of the year. 

RDIF, added that Stelis — the biopharma unit of global pharmaceutical company Strides — will work with the Russian wealth fund to provide supplies "beyond the initial agreement."

RDIF head Kirill Dmitriev said that the "significant vaccine volumes" produced with Stelis "will help widen access to the vaccine on a global scale."

RDIF said Friday that 52 countries have approved the use of Russia's Sputnik V, named after the Soviet-era satellite. 

Moscow registered the jab in August before large-scale clinical trials, but leading medical journal The Lancet has since said it is safe and over 90% effective.

Some Western countries have been wary of Sputnik over concerns the Kremlin would use it as a soft power tool to advance its interests.

Read more about: Sputnik V , Coronavirus , Vaccine

A Message from The Moscow Times:

Dear readers,

We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."

These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.

We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.

By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.

Once
Monthly
Annual
Continue
paiment methods
Not ready to support today?
Remind me later.

Read more

lifting the veil

Putin Reveals He Took Russia’s Sputnik V Coronavirus Vaccine

The Kremlin previously said it would keep the name of the Russian-made vaccine that Putin received this spring a “secret.”
heightened scrutiny

Russia Says Sputnik V Vaccine Does Not Cause Blood Clots

Rare cases of blood clots among those who received the Johnson & Johnson and AstraZeneca jabs have disrupted rollouts in some countries.
DANGEROUS MUTATION

Russia’s Sputnik V Vaccine Less Effective Against South African Variant – U.S. Study

Sputnik V developers have criticized the study, branding the conclusions and methodology “weak.” 
cost competition

Russia’s Coronavirus Vaccine More Expensive for Africa Than Western Jabs – FT

The Russian Direct Investment Fund maintains that Sputnik V's $9.75 price tag “is the same for all markets.”